Background: Understanding the processes that control selective eosinophilia is of fundamental importance in a variety of human diseases (e.g., allergies, parasitic infections, malignancy). Interleukin 5, an eosinophil-specific growth and activating factor, and eotaxin appear to collaborate in this process. Eotaxin is a recently described chemotactic factor that belongs to the C-C (or ,B) chemokine family and has been implicated in animal and human eosinophilic inflammatory states. We have recently reported the molecular characterization of murine eotaxin and now report the biological properties of purified recombinant murine eotaxin in vitro and in vivo in the presence or absence of interleukin 5 (IL-5) in mice. Materials and Methods: Murine eotaxin was expressed in bacteria and purified by affinity chromatography and HPLC. Activity was tested in vitro by examining chemotactic and calcium flux responses of purified murine leukocytes. Additionally, desensitization of calcium flux responses to other chemokines, eosinophil survival assays, and basophil histamine release were examined. Finally, eotaxin was delivered to wild-type or IL-5 transgenic mice and the host response was examined.
I'Department of Pathology and Laboratory Medicine, University of
Pennsylvania Medical System, Philadelphia, Pennsylvania, U.S.A.
ABSTRACT Background: Understanding the processes that control selective eosinophilia is of fundamental importance in a variety of human diseases (e.g., allergies, parasitic infections, malignancy). Interleukin 5, an eosinophil-specific growth and activating factor, and eotaxin appear to collaborate in this process. Eotaxin is a recently described chemotactic factor that belongs to the C-C (or ,B) chemokine family and has been implicated in animal and human eosinophilic inflammatory states. We have recently reported the molecular characterization of murine eotaxin and now report the biological properties of purified recombinant murine eotaxin in vitro and in vivo in the presence or absence of interleukin 5 (IL-5) in mice. Materials and Methods: Murine eotaxin was expressed in bacteria and purified by affinity chromatography and HPLC. Activity was tested in vitro by examining chemotactic and calcium flux responses of purified murine leukocytes. Additionally, desensitization of calcium flux responses to other chemokines, eosinophil survival assays, and basophil histamine release were examined. Finally, eotaxin was delivered to wild-type or IL-5 transgenic mice and the host response was examined.
Results: Eotaxin had activity only when the recombinant molecule had the native mature amino tenninus and contained the first 25 amino acids of the mature protein. It was active in vitro at an effective concentration between 10 and 100 ng/ml in both chemotaxis and calcium flux assays toward eosinophils, but not macrophages or neutrophils. Furthermore, intranasal or subcutaneous application of eotaxin selectively recruited large numbers of eosinophils into the mouse lung and skin, respectively, only in the presence of interleukin 5. Macrophage inflammatory protein-la, a related C-C chemokine active on eosinophils, and eotaxin were not able to cross-desensitize. Eotaxin had no affect on the in vitro survival of eosinophils and did not induce basophil histamine release.
Conclusions: Mouse eotaxin is an eosinophil specific chemoattractant that has a markedly enhanced effect in vivo in the presence of another eosinophil selective cytokine IL-5, and utilizes a signal transduction receptor pathway that is distinct from that utilized by macrophage inflammatory protein-la. This data suggests that the development of tissue eosinophilia in vivo involves a two-step mechanism elicited by interleukin 5 and eotaxin.
INTRODUCTION
The occurrence of selective eosinophilia in a variety of human diseases (e.g., allergic disorders, parasitic infections, malignancy) suggests the importance of molecules specific to the regulation of eosinophil proliferation and tissue accumulation. Two molecules that appear to be involved in this process are interleukin 5 (IL-5) (1), an eosinophil selective growth and survival factor, and eotaxin, a recently described eosinophil active C-C chemokine (2) (3) (4) (5) .
The chemokines are a family of 8-to 10-kD chemoattractive cytokines which have been divided into three groups depending upon the primary sequence of the first two cysteines (6) . The C-X-C and C-C families are generally active on neutrophils and macrophages, respectively, and map to distinct chromosomal loci. Recently, a third family has been identified based on the presence of a single -C-and appears to be active toward lymphocytes (7) . Chemokines induce chemotactic responses by binding to seven transmembrane-spanning G protein-linked receptors that result in transient increases in intracellular calcium (8) . The chemokines active toward eosinophils include the C-C chemokines: RANTES, macrophage inflammatory protein (MIP)-1 a, monocyte chemoattractant protein (MCP)-2 and -3, and eotaxin (9) (10) (11) . Although five distinct C-C chemokine receptors (CC CKR) have been identified (12-16) eosinophils appear to express only two of these (CC CKR-1 and -3) (Refs. 14, 15, and 17, and J.-L. Gao et al., submitted).
RANTES and MIP-l1a cross-desensitize the calcium flux response in human eosinophils presumably via CC CKR-1 (10) . However, it has been unclear which receptor is utilized by eotaxin.
Eotaxin was originally described as the chief eosinophil chemoattractive activity induced by allergen in a guinea pig model of allergic disease (2). We and others subsequently identified the guinea pig, mouse, and human eotaxin genes (2) (3) (4) (5) . High levels of eotaxin mRNA are detectable constitutively in multiple healthy tissues and may be responsible for promoting the baseline homing of eosinophils. Eotaxin mRNA is further increased during the early part of eosinophil recruitment in inflammatory models in animals and appears to be increased in the inflammatory lesions of patients with inflammatory bowel disease (3, 4, (18) (19) (20) (21, 22) . Conversely, the overproduction of IL-5 in transgenic mice (with a T cell promoter) results in massive eosinophilia (23) . This eosinophilia is limited to the hematopoietic organs and the mice are generally healthy, suggesting that other tissue recruitment factors (e.g., chemokines) are necessary to produce tissue eosinophilia. In a recent report in guinea pigs, eotaxin was found to cooperate with IL-5 in inducing cutaneous eosinophilia (24) . The biological properties of the purified mouse eotaxin protein have not been reported. In this report, we generate purified recombinant murine eotaxin and examine its cellular specificity at a wide range of doses, its ability to transduce calcium flux and cross-desensitize cellular signaling by other chemokines, and its effect in vivo in the absence and presence of the IL-5 transgene.
MATERIALS AND METHODS

Recombinant Eotaxin Expression and Purification
Recombinant murine eotaxin beginning with the putative mature amino terminal histidine24 and terminating with the carboxy-terminal proline97 was amplified by polymerase chain reaction (PCR) using the murine eotaxin cDNA as a template. The PCR primers were designed to amplify a sequence that contained BamHl sites on both ends and that would encode a protein with an amino-terminal factor Xa site (IEGR). Amplified cDNA was subsequently subcloned using a TA cloning kit (Invitrogen, San Diego, CA, U.S.A.) and confirmatory sequencing was performed. The eotaxin construct was liberated by BamHl digestion, cloned into the BamHl sites of Qiaexpress vector PQE8 (Qiagen Inc., Chatsworth, CA, U.S.A.), and then transformed into the Escherichia coli strain M15. Expression of eotaxin in pQE8 results in a fusion protein containing an amino-terminal Met-Arg-Gly-Ser-(His)6 tag and the addition of Gly-Ser on the carboxy-terminal end (Fig. IA, below) .
Recombinant M15 E. coli containing the PQE8 plasmid engineered to express murine eotaxin were inoculated into Luria-Bertani medium supplemented with ampicillin (100 mcg/ ml) and kanamycin (25 mcg/ml) and grown with shaking at 37°C to an OD600 = 0.7. Isopropyl ,B-D-thiogalactopyranoside was then added to 2 mM final concentration to induce protein expression. Cultures were incubated for another 4 hr and then centrifuged at 4000 X g for 20 min at 40C. The pellet was frozen at -20°C overnight. After thawing for 15 min on ice, the bacterial pellet was resuspended in 6 M guanidine HCI, 0.1 M sodium phosphate, and 0.01 M Tris HC1 (pH 8.0) at 5 ml/g wet bacteria. The suspension was sonicated on ice using a Branson model 450 sonifier with a microtip attachment at constant cycles and output of 4 for a total of 8 min (four 2-min cycles). The sample was then centrifuged at 9500 X g for 15 min at 40C to remove cellular debris. The clarified supernatant was applied to a nickel-NTA (ProBond, Invitrogen) chromatography column that had been equilibrated by resuspension in the above 6 M guanidine buffer. The column was washed with 10 Four hours after instillation, mice were euthanized by carbon dioxide inhalation, the thorax opened and the trachea exposed. A 24-gauge ball-tip needle on a 1-cc syringe was introduced into the airway via a small incision on the ventral surface of the trachea. Phosphate-buffered saline (0.8 ml) containing 10% fetal calf serum and 1 mM EDTA was infused then retrieved using the 1-cc syringe, and the number of cells in the bronchoalveolar lavage (BAL) fluid was enumerated using a hemocytometer. A 100-,ul aliquot of the fluid was applied to a glass slide by centrifugation at 400 RPM for 4 min in a Shandon Cytospin II centrifuge. The slides were air dried for 30 min before staining with Diff-Quik (Baxter Scientific Products, McGaw Park, IL, U.S.A.). The leukocyte differential was determined and the absolute eosinophil count derived as the product of the absolute leukocyte count and the eosinophil fraction on the leukocyte differential. After intratracheal BAL was performed, the lungs were fixed in 10% neutral buffered formalin under mild vacuum. Tissues were embedded in paraffin and 5-gtm sections were cut and stained by hematoxylin and eosin.
In other experiments, IL-S transgenic or wild-type mice (CBA/CaJ) were subcutaneously injected with 100 ,ul of phosphate-buffered saline alone or containing 0.1-1000 pmoles of eotaxin. After 1, 3, 6, 24, 48, and 72 hr, the mice were euthanized by carbon dioxide inhalation and the tissue surrounding the injection site was removed and fixed in neutral buffered formalin. Tissue sections (10 ,um) were cut and stained with hematoxylin and eosin or giemsa.
Calcium Flux Assays
Murine eosinophils were isolated from IL-5 transgenic mice (23) . These mice develop splenomegaly, with eosinophils accounting for -30% of the splenocytes. Eosinophils were purified from the spleen using immuno-magnetic separation to remove the contaminating splenocytes. Splenocytes were subjected to hypotonic lysis to remove erythrocytes and the remaining leukocytes were labeled with anti-Thy-I (M5/49), anti-B220 (6B2), and anti-Lyt-2 (53-6.7 (26) .
Eosinophil Survival Assays Survival was calculated as previously described (27) . Briefly, murine eosinophils were purified as described above and resuspended in RPMI-1640 medium supplemented with 10% fetal bovine serum, and 1 (33) . The purified histidine-tagged eotaxin protein was subjected to Xa digestion. SDS-PAGE analysis of the factor Xa digested (his)6-tagged eotaxin revealed two digestion products (-6 and -9 kD) which were subsequently purified by reverse phase HPLC and subjected to N-terminal sequencing. Sequence analysis revealed that the protein preparation containing the larger band (Lane 5 in Fig. 1B) (Fig. 2) . When each protein was tested for their biological activity on eosinophils, the purified eotaxin liberated at the internal cleavage site (B) had no activity, whereas the protein generated with the native amino terminus (A) had activity (data not shown). Additionally, the fraction that contained both bands had full biological activity, indicating that product B did not have significant inhibitory activity. These results demonstrate that eotaxin generated in bacteria is biologically active only when there is a native mature amino terminus. Eosinophils were exposed to purified eotaxin at doses ranging from 0 to 1000 ng/ml and exhibited a dose-dependent increase in their chemotactic response (Fig. 3A) between 5 and 50 ng/ml. Macrophages were similarly tested and exhibited no chemotactic response to eotaxin at any dose tested (Fig. 3B) . As positive controls (6), replicate macrophages responded to murine MIP-a and FMLP (Fig. 3B) . Additionally, neutrophils exhibited no response to eotaxin whereas they had a strong response to control agents (6) , human IL-8 and FMLP (Fig 3C) . These results demonstrate that purified eotaxin, at a wide range of doses, is a direct and selective chemotactic cytokine for eosinophils in vitro. (Fig. 4) . The threshold for observing an effect was 15 ng/ml and a maximum effect was seen at -100 ng/ml with a plateau at higher concentrations. Intracellular calcium concentrations were calculated to be -75 nM in resting eosinophils and 220 nM in eosinophils stimulated with eotaxin (1000 ng/ml). (Fig. 7A) . However, the same cells were not desensitized to respond to murine MIP-la (Fig. 7A) . Conversely, murine MIP-1 a induced a modest calcium flux in eosinophils (Fig. 7B) . This resulted in self-desensitization, but did not affect subsequent cellular signaling by eotaxin (Fig.  7B) . The ability of eotaxin to desensitize to itself was dose dependent and was not seen at a lower dose of eotaxin (30 ng/ml) (Fig. 7C) . Additionally, murine MCP-1 and murine MIP-1,B (Fig. 7D) Calcium flux in eosinophils in response to various chemokines (A) Eosinophils were exposed to eotaxin (1000 ng/ ml) and subsequently to another dose of eotaxin (1000 ng/ml) followed by MIP-la exposure (200 ng/ml). (B) Eosinophils were exposed to MIP-la (1000 ng/ml) and then to eotaxin (250 ng/ml). (C) Eosinophils were exposed to a lower concentration (30 ng/ml) and then to a higher concentration (1000 ng/ml) of eotaxin. (D) Cells were exposed to MCP-1 (200 ng/ml), MIP-113 (200 ng/ml), and then to eotaxin (1000 ng/ml). (35, 36) . Eotaxin was therefore delivered to anesthetized mice by intranasal application of 0.5 and 5.0 nmoles or normal saline alone. Four hours after treatment, the mice were sacrificed and the cellular count and composition in the BAL was analyzed. In wild-type mice, there was no consistent difference in the total number of BAL cells (data not shown) or the cellular composition (Fig. 8A) . In two of six eotaxin-treated mice, there was a detectable increase in the number of BAL eosinophils (Fig. 9) .
IL-5 transgenic mice have large numbers of eosinophils in the hematopoietic organs and blood but few in the tissue such as the lungs.
These eosinophils are likely to be primed to respond to eotaxin since IL-5 has been shown to prime human eosinophils to respond to other stimuli (27) including chemoattractants such as RANTES, PAF, and FMLP (37,38). Consequently, it was of interest to determine if the application of eotaxin to IL-5 transgenic mice would elicit pulmonary eosinophilia. When eotaxin was delivered to these mice, there was a marked increase in the total number of BAL cells which was entirely due to an increase in the number of eosinophils. Normal saline-treated IL-S transgenic mice had a mean of 4.3% eosinophils and this level rose to a mean of 22 and 88% following 0.5 and 5.0 nmoles of intranasal eotaxin, respectively (Fig. 8B) . No other cell type was recruited into the BAL fluid (Fig. 8B) . When the total eosinophil count was determined in the BAL following eotaxin treatment, there was a large increase in the number of eosinophils. The normal saline-treated mice had a mean of 3.2 X 103 eosinophils and the eotaxin-treated mice had a mean of 5.0 X 104 and 2 x 106 eosinophils after 0.5 and 5.0 nmoles of eotaxin, respectively (Fig. 9) . No increase was seen in other cell types.
Representative photomicrographs of BAL cells recovered following normal saline treatment (Fig. lOA) or eotaxin treatment (Fig. lOB sections from the lungs of mice were also examined. IL-5 transgenic mice treated with eotaxin showed a dense eosinophilic infiltrate. The majority of the eosinophils were present in alveolar capillaries with marked egress into the alveolar airspace (Fig. 10C ). In addition, increased numbers of eosinophils were noted in the peribronchiolar connective tissue and within small vessels in the interstitium. In contrast, IL-5 transgenic mice treated with normal saline showed only scattered pulmonary eosinophils, located predominantly within alveolar capillaries (Fig. 1 OD) . 1996 Additionally, strain matched wild-type mice treated with eotaxin exhibited no significant pulmonary changes (data not shown). The dose of intranasal eotaxin required to induce pulmonary eosinophilia was relatively high compared with that required to induce cutaneous eosinophilia in guinea pigs (2, 24) . It was therefore of interest to administer murine eotaxin via another route that allowed its affects to be examined directly at the site of administration. Eotaxin was injected subcutaneously into IL-5 transgenic and wild-type mice, and the local tissue was analyzed for the inflammatory infiltrate. Analysis after 1 hr revealed leukocyte margination and perivascular infiltrates composed exclusively of eosinophils in the IL-5 transgenic mice (Fig. lOE) . No effect was seen in wild-type mice at doses of 0.1-1000 pmoles when the samples were analyzed at 1 hr to 3 days after injection. In IL-5 transgenic mice, an increase in tissue eosinophilia was appreciated at 1-10 pmoles of eotaxin and modestly increased at the higher doses. Thus, eotaxin selectively induces large numbers of eosinophils in the presence of the Eosinophil Survival Eosinophil tissue survival is thought to depend upon inhibition of apoptosis by eosinophil directed survival factors such as IL-5 (27, 39) . In the mouse system, the ability of IL-5 to maintain eosinophil survival has not been tested. It was also of interest to determine if eotaxin was able to maintain eosinophil survival. Murine eosinophils (n = 2) from IL-5 transgenic mice were found to depend upon IL-5 for their survival in vitro. Whereas only 3.1 ± 2.1% (mean ± SD) of the eosinophils survived in medium alone, 83 ± 5% survived in the presence of 5 pM IL-5. In contrast, eotaxin did not enhance the survival of replicate eosinophils since only 1 ± 0.2, 1.5 ± 0.6, 5.6 ± 2.5, 2.9 ± 0.3, and 2.2 ± 0.4% of the eosinophils survived at 50, 100, 250, 500, and 1000 ng/ml of eotaxin.
Human Basophil Histamine Release Chemokines related to eotaxin (e.g., MCP-1 and -3, MIP-1 a) have been shown to stimulate the release of histamine from cytokine primed basophils from some donors (10, (28) (29) (30) (31, 32) . Although eotaxin from guinea pigs, mice, and humans have a different first amino acid than MCP-1, -2, and -3, the important role of the amino terminus appears to be conserved. Biological activity was also shown to be dependent upon the presence of the first 25 amino acids since an eotaxin derivative lacking the first 25 amino acids had no biological activity. The requirement for intact amino-terminal amino acids has important implications for the design of therapeutic eotaxin analogs.
Recombinant eotaxin protein was found to be present as a mixture of higher molecular species most likely representing protein aggregation. It is interesting that eotaxin lacking the first 25 amino acids (Lane 3 in Fig. 1B ) also appeared to aggregate, indicating that the first 25 amino acids do not appear to be necessary for protein aggregation. Aggregation is known to occur with other chemokines. In the case of IL-8, although aggregation occurs, the monomer maintains full biological activity (40) . It remains to be determined if eotaxin aggregation serves an important function. Nevertheless, using a protein preparation that contained a mixture of aggregates, eotaxin delivered direct and potent chemotactic and calcium flux responses to murine eosinophils, with a peak effect noted at -100 ng/ml.
It was important to determine if the selectivity of eotaxin for guinea pig eosinophils (which has only been addressed in vivo) is applicable in other species. Since guinea pigs contain larger numbers of baseline eosinophils than mice or humans and is a species in which it is relatively easy to induce allergic models (41) , it was possible that eotaxin's unique properties may not be extendible to other species. We first addressed this selectivity in vitro and found that murine eotaxin stimulated eosinophils and not neutrophils, macrophages, or basophils. This selectivity is similar to that we observed for human eotaxin on cells from nonatopic or mildly atopic donors (4) . In a recent report, human eotaxin was shown to selectively induce eosinophil transmigration through endothelial cells and to have only a small effect on monocytes at 1000 ng/ml (5). Thus, in contrast to all other C-C chemokines, eotaxin has no significant effect on macrophages in vitro.
We next examined the selectivity of eotaxin in vivo and demonstrated that the application of eotaxin to wild-type mice produced only a small and variable eosinophil recruitment. In contrast, in the presence of IL-5, eotaxin induced a marked eosinophil selective recruitment. Although the dose of eotaxin that was required to induce this effect was high, only a small amount of the eotaxin delivered to the nose is likely to be deposited in the lung, the organ that was analyzed. During the preparation of this manuscript, purified human eotaxin was shown to selectively induce eosinophils when injected into the skin of a single rhesus monkey (5) . In another report, the direct administration of mouse eotaxin (via a crude supernatant from eotaxin transfected myeloma cells) to the lung of wild-type mice was able to induce a selective eosinophfil recruitment (20) . Although the effect in the lungs was considerably smaller (-10-fold) than the effect we observed in the lungs of IL-5 transgenic mice (-500-fold increase), it is likely that other products present in the crude supernatant were able to enhance the effect of eotaxin. Alternatively, the differences in these studies may result from variations between the animals (e.g., their endogenous levels of IL-5). The strength of our study is that purified eotaxin alone was delivered and found to recruit huge numbers of eosinophils into the mouse lung only in the presence of IL-5. The cooperativity with IL-5 is similar to that reported in the guinea pig (24) . The effect of IL-5 is likely to be the result of increasing both the eosinophil pool (24) Multiple chemokines often bind to the same receptor. It has been unclear if eotaxin binds to eosinophils via a receptor that is shared with other chemokines. Eosinophils preferentially express two C-C chemokine receptors, CC CKR-1 and CC CKR-3 (Refs. 14, 15, and 17, and J.-L. Gao et al., submitted). Eosinophils and macrophages are thought to use the same receptor to respond to MIP-la, RANTES, and possibly MCP-3, presumably CC CKR-1 (9, 11, 42) . Guinea pig eotaxin and human RANTES appear to compete for the same receptor on human eosinophils (2). However, human RANTES is not a functional agonist for guinea pig eosinophils and it is therefore difficult to draw any firm conclusions from these studies. One way to begin to determine if eotaxin shares a binding site with these other chemokines is to determine if eotaxin and other chemokines cross-desensitize eosinophils to subsequent cellular signaling. Murine MIP-la (since this was the only murine eosinophil active chemokine available) was studied with murine eotaxin. Eotaxin consistently delivered a larger calcium flux than MIP-1a in eosinophils, perhaps indicating that eotaxin is more physiologically active on eosinophils. Neither chemokine was able to cross-desensitize to each other indicating that they used distinct receptor pathways. It was recently reported that human RANTES and MCP-3 (which are not available for study in mice) but not MIP-1a were able to desensitize human eosinophils to human eotaxin (5) . Interestingly, these investigators found that treatment of human eosinophils with human eotaxin caused complete desensitization to subsequent signaling with MIP-lIa, RANTES, and MCP-3. In our study in mice, we did not find that eotaxin desensitized to MIP-1a. This may be related to a difference between species or modification of the receptor signaling pathway by IL-5 in vivo (since the mouse eosinophils were isolated from IL-5 transgenic mice). Alternatively, the difference may be due to the fact that the eosinophils from the study by Ponath et al. were examined only from patients with high levels of eosinophilia. Such eosinophils often have different characteristics from eosinophils from patients without eosinophilia (37) . Nevertheless, the lack of desensitization of eotaxin to subsequent MIP-1a signaling, indicates that eosinophils utilize at least two distinct chemokine receptor pathways. The eotaxin receptor is likely to be conserved between mice and human since we have recently been able to demonstrate that eotaxin (and not MIP-la) induces a calcium flux in cells transfected with murine CC CKR-3 (J.-L. Gao et al., submitted). It is interesting that eosinophils appear to express much higher levels of CC CKR-3 than CC CKR-1 and the expression of CC CKR-3 is very restricted to eosinophils. This may explain the failure of eotaxin to liberate histamine release from basophils and the remarkable selectivity of eotaxin. The exact binding domains on eotaxin for eosinophil receptor signaling are not known; however, amino acids within the first 25 residues are critical since the eotaxin derivative lacking these amino acids has no activity.
The results of this study demonstrate that eotaxin is highly selective for eosinophils in vivo and in vitro, has markedly enhanced chemoattractive activity for eosinophils in the presence of IL-5 in vivo, and utilizes a receptor pathway that is not shared with MIP-1 a. This suggests that the development of tissue eosinophilia in vivo involves a two-step mechanism elicited by interleukin 5 (or possibly other eosinophil growth factors) and eotaxin. A further understanding of eotaxin and its interaction with IL-5 may lead to new therapeutic modalities for treating allergic and malignant diseases.
